Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 299Carcinoma, Non-Small-Cell Lung 224Neoplasms 192Prostatic Neoplasms 163Multiple Myeloma 139Neoplasm Metastasis 117Melanoma 112Colorectal Neoplasms 107Leukemia, Myeloid, Acute 105Lung Neoplasms 98Lymphoma 96Ovarian Neoplasms 84Squamous Cell Carcinoma of Head and Neck 77Lymphoma, Non-Hodgkin 73Leukemia, Lymphocytic, Chronic, B-Cell 72Triple Negative Breast Neoplasms 64Pancreatic Neoplasms 64Myelodysplastic Syndromes 64Hematologic Neoplasms 60Parkinson Disease 4, Autosomal Dominant Lewy Body 59Head and Neck Neoplasms 59Glioblastoma 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Recurrence 56Leukemia 55Sarcoma 50Brain Neoplasms 49Lymphoma, Large B-Cell, Diffuse 48Carcinoma, Hepatocellular 47Lymphoma, Follicular 46

Interventions

Random Allocation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoid Tumor × 1 year × Clear all
NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡